Biopharmaceutical startup Everest Medicines on Friday announced it has raised $310 million in a Series C funding round to finance the clinical development and commercialisation of its drug candidates.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
